Multiple Leukemia Translocation Assay
Signature LTx
Indication
For initial diagnostic samples of blood and bone marrow aspirate to detect the presence of 11 different leukemia-associated fusion transcripts (see list below).
Methodology
Extracted RNA is analyzed by reverse transcription multiplex PCR with detection on the Luminex cytometer using a multiprobe bead array method (Asuragen LTX assay).
Test Parameters
Qualitative detection of any of the fusion transcripts in list below. The sensitivity of detection of a particular fusion transcript varies between 1-10% translocation-bearing cells depending on the particular tumor type. This test is not appropriate for minimal residual disease (MRD) assessment.
Chromosomal aberration
- t(9;22)(q34;q11) major
- t(9;22)(q34;q11) major
- t(9;22)(q34;q11) minor
- t(15;17)(q22;q21)
- t(15;17)(q22;q21)
- inv(16)
- inv(16)
- t(8;21)(q22;q22)
- t(1;19)(q23;p13)
- t(4;11)(q12;q23)
- t(12;21)(p12;q22)
Transcript type
- BCR-ABL b3a2
- BCR-ABL b2a2
- BCR-ABL e1a2
- PML-RARA short form
- PML-RARA long form
- CBFb-MYH11 type A
- CBFb-MYH11 type D
- AML1-ETO
- E2A-PBX-1
- MLL-AF4 (e9/e5 & e10e4)
- TEL-AML1
Turnaround Time: Four to five days
Sample Requirements
- 5 mls peripheral blood (PB) in purple top tube (EDTA Vacutainer), sent on wet ice
or - 2-5 ml of bone marrow aspirate (BM), sent on wet ice
or - 2.5 µg of purified RNA, sent on dry ice
CPT Codes
83891 (RNA Isolation), 83902, 83896x7, 83900, 83901x4, 88384
The CPT codes provided are based on AMA guidelines and are for informational purposes only. CPT coding is the sole responsibility of the billing party. Please direct any questions regarding coding to the payer being billed.